AbbVie sales and marketing update

AbbVie entered an agreement with the ADAP Crisis Task Force (ACTF) to provide its HCV regimen Viekira Pak at an undisclosed discount to state AIDS Drug Assistance Programs (ADAPs). In December, FDA approved Viekira Pak with or without ribavirin to treat HCV genotype 1 infection in patients with and without compensated cirrhosis, including those co-infected with HIV.

Read the full 576 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE